The diagnoses of the patients in the 2 groups are given in Table 1 . Table 2 gives the bacteriological analysis from the pharyngeal swabs.
In some cases sterilization of bronchial secretions was already detected on the sixth day and elimination of the pathogens was always complete by the eighth day. There were, however, 3 cases (2 in Group I and I in Group If) in which bacteriological analysis did not detect microorganisms either before or at the end of therapy. Tables 3 and 4 show respectively for Groups I and 1I the laboratory data for patients before and at the end of therapy. Most parameters were not From a review of the data on the antibacterial activity of cefuroxime, both in vivo and in vitro, the information provided to us on animal toxicology and the results of pharmacological studies including animal histopathology, it was evident that sodium cefuroxime would be a good antibiotic for study in patients suffering from infectious diseases of the chest.
Trial Design
Results are presented of a study using sodium cefuroxime in patients in the Chest Clinic in Messina, Italy. Twenty-seven patients (22 males and 5 females) aged between 29 and 74 years (mean age 55.4) were included in the trial. The clinical evaluation of the patients was made from the history and the evidence of signs and symptoms, confirmed by radiological examination of the chest and supported by various laboratory investigations and by bacteriology. In making our clinical assessment of these patients, concurrent diseases were taken into consideration. In order to obtain verification of the drug's clinical efficacy and to monitor the effect within the body, all the parameters of investigation carried out before the patients entered into the study were repeated during and at the end of treatment, so that radiological, bacteriological, and laboratory controls existed for all parameters. Bacteriological examination of bronchial secretion was carried out before treatment and again on the third and sixth days of therapy, as well as on the third and eighth day after the cessation of treatment. All patients in the study were given cefuroxime for 8 days and as the patients were continuously observed and clinically assessed, the dosage could be modified according to the physician's opinion. In all instances patients were treated by i.m. injection on a twice daily regimen, either with 750 mg or 1 g.
Results
In reviewing the results, patients have been divided into 2 groups. In the first group (Group I) the dosage was 750 mg twice daily by i.m. injection. It includes 18 patients (15 males and 3 females) between the ages of 29-74. The second group of patients (Group II) were given 1 g twice daily by i.m. injection. They were 9 patients (7 males and 2 females) with ages ranging from 35-71 years (mean age 56.7). 
Conclusion
It is apparent from these results that both sub-jectively and objectively during the observation period of these patients, there was a clear improvement in their clinical condition. The clinical picture of their chests leaves no doubt that they are improved at the end of treatment, with a reduction in their bronchopulmonary sysmptoms, i.e. cough, catarrh, dyspncea. It is encouraging to see that even in conditions where the patients had chronic chest diseases and irreversible parenchymal changes, they had still improved considerably during the study. Likewise we were impressed with the therapeutic results in this group of patients with low doses of the antibiotic (i.e. 750 mg twice daily i.m.) which in our opinion confirms the high activity of this drug in vitro against most of the commonly found pathogenic agents in the chest.
We saw no intolerance to this therapy in any of our patients, and in our examination of the hepatic and renal effects, no changes were noted. Any changes in laboratory tests on the blood or urine were always within the normal range and we did not attribute them to any toxic effect of cefuroxime. We therefore conclude that as a result of our clinical investigations in patients with moderate and severe chest diseases and infection, cefuroxime is a good antibiotic, but we still need more extensive studies to delineate its true place in the armamentarium of clinicians treating chest infections.
